lunes, 16 de marzo de 2026
Doctors treating sickle cell disease report the highest burnout rates
https://www.news-medical.net/news/20260316/Doctors-treating-sickle-cell-disease-report-the-highest-burnout-rates.aspx
Physicians who treat sickle cell disease face some of the most complex and resource-intensive care in medicine, and a national survey now shows they experience markedly higher burnout, raising concerns about workforce sustainability and patient care.
Scientists show gut bacteria can reach the brain in mice and reveal a potential vagus nerve pathway
https://www.news-medical.net/news/20260315/Scientists-show-gut-bacteria-can-reach-the-brain-in-mice-and-reveal-a-potential-vagus-nerve-pathway.aspx
A new mouse study reveals that under certain dietary conditions, gut bacteria can reach the brain without entering the bloodstream, suggesting a possible vagus nerve route and raising new questions about the gut–brain connection.
Potential Treatment for ROSAH Syndrome Accepted into FDA’s Rare Disease Evidence Principles Process Mar 12, 2026 | Autoimmune / Autoinflammatory Disorders +...
https://checkrare.com/
The US Food and Drug Administration (FDA) has accepted DF-003 into the FDA Rare Disease Evidence Principles Process (RDEP) for the potential treatment of ROSAH syndrome. ROSAH (retinal dystrophy,... AND MORE!!!
CLINICAL PERSPECTIVES +++++ +++++ +++++ +++
CLINICAL PERSPECTIVES
MajesTEC-9 Clinical Trial of Teclistamab in Patients With Multiple Myeloma
https://checkrare.com/majestec-9-clinical-trial-of-teclistamab-in-patients-with-multiple-myeloma/
Roberto Mina, MD, Associate Professor at Winship Cancer Institute of Emory University, discusses the Majestec-9 clinical trial of Tecvayli (teclistamab) in patients with multiple myeloma (MM).
Long-Term Outcomes From the PIONEER Study in Patients With Indolent Systemic Mastocytosis
https://checkrare.com/long-term-outcomes-from-the-pioneer-study-in-patients-with-indolent-systemic-mastocytosis/
Tsewang Tashi, MD, Hematologist at the Huntsman Cancer Institute at the University of Utah, discusses long-term data from the PIONEER clinical trial examining the use of avapritinib in patients with indolent systemic mastocytosis (ISM).
Using Artificial Intelligence to Analyze Castleman Disease Histopathology
https://checkrare.com/using-artificial-intelligence-to-analyze-castleman-disease-histopathology/
Robert S. Ohgami, MD, PhD, Professor of Pathology, University of Utah, and Founding Vice President and Chief Medical Director, ARUP Institute for Research and Innovation, discusses the utilization of artificial intelligence (AI) to analyze Castleman disease (CD) histopathology.
Elritercept’s Effect on Transfusion Independence in Patients With Myelodysplastic Syndromes
https://checkrare.com/elritercepts-effect-on-transfusion-independence-in-patients-with-myelodysplastic-syndromes/
Lynette Chee, PhD, Hematologist at The Royal Melbourne Hospital/ Peter MacCallum Cancer Centre, discusses elritercept’s effect on transfusion independence (TI) in patients with myelodysplastic syndromes (MDS).
52-Week Results From the VERIFY Clinical Trial of Rusfertide in Patients With Polycythemia Vera
https://checkrare.com/52-week-results-from-the-verify-clinical-trial-of-rusfertide-in-patients-with-polycythemia-vera/
Andrew T. Kuykendall, MD, VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center, discusses 52-week results from the VERIFY clinical trial testing rusfertide in patients with polycythemia vera (PV).
Results from the XTEND-ed Clinical Trial Evaluating Efanesoctocog Alfa for the Treatment of Patients With Hemophilia A
https://checkrare.com/results-from-the-xtend-ed-clinical-trial-evaluating-efanesoctocog-alfa-for-the-treatment-of-patients-with-hemophilia-a/
Lynn Malec, MD, Versiti Blood Research Institute and Medical College of Wisconsin, discusses results from the XTEND-ed clinical trial evaluating efanesoctocog alfa for the treatment of patients with hemophilia A.
Bleximenib Combination Therapy for Patients With Acute Myeloid Leukemia
https://checkrare.com/bleximenib-combination-therapy-for-patients-with-acute-myeloid-leukemia/
Hartmut Döhner, MD, Professor of Medicine and Medical Director of the Department of Hematology and Oncology, Ulm University, Germany, discusses bleximenib combination therapy for treatment of patients with acute myeloid leukemia (AML).
Rare Diseases in Ireland – New Efforts to Improve Access to Care
https://checkrare.com/rare-diseases-in-ireland-new-efforts-to-improve-access-to-care/
Each country takes a different approach to rare diseases, from the way it defines the term to the health policies it implements to its approach to research.
SWITCH Clinical Trial Design for Patients With Hemophilia A
https://checkrare.com/switch-clinical-trial-design-for-patients-with-hemophilia-a/
Guy Young, MD, Children’s Hospital Los Angeles, discusses the SWITCH clinical trial design for patients with hemophilia A.
Phase 2 Results of Dusquetide in the Treatment of Oral Ulcers Caused by Behçet’s Disease
https://checkrare.com/phase-2-results-of-dusquetide-in-the-treatment-of-oral-ulcers-caused-by-behcets-disease/
Recently, results from a phase 2a study evaluating SGX945 (dusquetide) for the treatment of Behçet’s disease were published in Rheumatology (Oxford).
Real World Safety Data of Enjaymo (Sutimlimab) in Patients With Cold Agglutinin Disease
https://checkrare.com/real-world-safety-data-of-enjaymo-sutimlimab-in-patients-with-cold-agglutinin-disease/
Catherine M. Broome, MD, Professor of Medicine and Director of Cellular Apheresis, Lombardi Cancer Center, MedStar Georgetown University, discusses real world safety data of Enjaymo (sutimlimab) in patients with cold agglutinin disease (CAD).
Long-term Efficacy of Rilzabrutinib in Patients With Immune Thrombocytopenia
https://checkrare.com/long-term-efficacy-of-rilzabrutinib-in-patients-with-immune-thrombocytopenia/
David Kuter, MD, DPhil, Professor of Medicine at Harvard Medical School, Massachusetts General Hospital, discusses treatment with rilzabrutinib in patients with immune thrombocytopenia (ITP).
Recent Data on Ravulizumab in Rare Hematologic Conditions
https://checkrare.com/recent-data-on-raulizumab-in-rare-hematologic-disorders/
Anita Hill, MD, PhD, Global Medical Head for Hematology & Nephrology and Transplant at Alexion, AstraZeneca Rare Disease, discusses recent data on ravulizumab in rare hematologic conditions.
Efficacy of Pozelimab + Cemdisiran To Treat Paroxysmal Nocturnal Hemoglobinuria
https://checkrare.com/efficacy-of-pozelimab-cemdisiran-to-treat-paroxysmal-nocturnal-hemoglobinuria/
Jun Ho Jang, MD, PhD, Professor, Division of Hematology-Oncology at Samsung Medical Center, discusses results from an open-label extension study testing pozelimab plus cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria (PNH), who previously received the combination therapy or received ravulizumab.
Treatment With Elritercept for Patients With Myelofibrosis
https://checkrare.com/treatment-with-elritercept-for-patients-with-myelofibrosis/
Ciro Rinaldi, MD, Consultant Hematologist and Professor of Hematology at United Lincolnshire Hospital, discusses treatment with elritercept for patients with myelofibrosis (MF).
Updated Phase 2 Results of Telquetamab + Teclistamab in Multiple Myeloma
https://checkrare.com/updated-phase-2-results-of-telquetamab-teclistamab-in-multiple-myeloma/
Saad Usmani, MD, Myeloma Specialist and Cellular Therapist at Memorial Sloan Kettering Cancer Center, discusses updated results from the phase 2 RedirecTT-1 study of telquetamab + teclistamab in patients with multiple myeloma (MM).
Results from the CARTITUDE-4 Clinical Trial in Multiple Myeloma
https://checkrare.com/results-from-the-cartitude-4-clinical-trial-in-multiple-myeloma/
Binod Dhakal, MD, Associate Professor of Medicine at Medical College of Wisconsin, discusses results from the CARTITUDE-4 clinical trial in patients with multiple myeloma (MM).
Results of Part 1a of the OLYMPIA-3 Study of Odronextamab+Chemotherapy in Diffuse Large B Cell Lymphoma
https://checkrare.com/results-of-part-1a-of-the-olympia-3-study-of-odronextamabchemotherapy-in-diffuse-large-b-cell-lymphoma/
Jean-Marie Michot, MD, Institut Gustave Roussy, France, discusses results from Part 1A (dose escalation) of the OLYMPIA-3 study of odronextamab plus chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL).
2026 Orphan Drugs: PDUFA Dates and FDA Approvals ++++++
FDA NEWS
2026 Orphan Drugs: PDUFA Dates and FDA Approvals
https://checkrare.com/2026-orphan-drugs-pdufa-dates-and-fda-approvals/
Rare diseases and orphan drugs are at the forefront of novel development and groundbreaking research. Almost half of all novel medications approved by the U.S. Food and Drug Administration (FDA) are orphan drugs. Below is the list of important regulatory dates for all orphan drugs for 2026.
Accelerated Approval Granted to Loargys (pegzilarginase) for the Treatment of ARG1 Deficiency
https://checkrare.com/accelerated-approval-granted-to-loargys-pegzilarginase-for-the-treatment-of-arg1-deficiency/
The US FDA has granted accelerated approval to Loargys (pegzilarginase-nbln) for the treatment of patients ages 2 years and older with arginase 1 deficiency (ARG1-D).
FDA Approves Venetoclax Combination Therapy for Adults With Chronic Lymphocytic Leukemia
https://checkrare.com/fda-approves-venetoclax-combination-therapy-for-adults-with-chronic-lymphocytic-leukemia/
The US FDA has approved Venclexta (venetoclax) in combination with acalabrutinib therapy for untreated adult patients with chronic lymphocytic leukemia (CLL).
FDA Approved Darzalex Faspro Combination Therapy for Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
https://checkrare.com/fda-approved-darzalex-faspro-combination-therapy-for-patients-with-transplant-ineligible-newly-diagnosed-multiple-myeloma/
The US FDA has approved Darzalex Faspro (daratumumab and hyaluronidase) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for the treatment of adults with newly diagnosed multiple myeloma (MM) who are ineligible for autologous stem cell transplant (ASCT).
Expanded Indication for Cablivi to Patients Ages 12 Years and Older With aTTP
https://checkrare.com/fda-expands-cablivi-caplacizumab-indication-to-patients-ages-12-years-and-older-with-attp/
The U.S. FDA has approved Cablivi (caplacizumab) for the treatment of pediatric patients ages 12 years and older with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange and immunosuppressive therapy.
FDA Approves Aqvesme (Mitapivat) for Treating Anemia in Alpha- and Beta-Thalassemia
https://checkrare.com/fda-approves-aqvesme-mitapivat-for-treating-anemia-in-alpha-and-beta-thalassemia/
The U.S. FDA has approved Aqvesme (mitapivat) for the treatment of anemia in adults with alpha- or beta-thalassemia.
Position-wise mutation analysis and temporal changes in SARS CoV-2 Envelope (E) protein variants Anwesa Saha [1,†] , Diganta Mukherjee [1,†] , Aparna Mukhopadhyay* [1]
https://www.academia.edu/3064-9765/2/4/10.20935/AcadMolBioGen8011
Abstract
SARS CoV-2 is a positive-sense, single-stranded RNA virus. The genome of the virus undergoes numerous mutations, making the development of universally effective drugs challenging. Among its structural proteins, the Envelope (E) protein acts as an ion transporter and virulence factor, making it a potential therapeutic target. Based on the literature available to date, we have identified several functionally important sites in the E protein. These include residues involved in lysosomal deacidification; those of the FYXY motif, involved in amyloid formation in the host; and the PDZ-binding DLLV motif. We focus our analysis on the significance of these residues while also searching for other interesting mutational patterns. In this study, we conducted a comprehensive mutational analysis of the SARS CoV-2 E protein utilizing bioinformatics, statistics, and structural modeling tools. Over 1.4 million sequences were retrieved from the NCBI virus database, filtered, clustered, and aligned chronologically. By employing a combination of web-based tools and in-house Python scripts, we analyzed per-residue Shannon entropy, mutation types, evolutionary pressure, and predicted structural impact (via ∆∆G). We observed a significant number of residues under diversifying selection. This suggests that new amino acids are being sampled at various positions in the protein, providing functional or structural benefits to the virus. A cyclical pattern of mutation and reversion was observed at position 9, stabilizing at a particular mutation. Similar trends appeared at position 11. These mutations may be functionally relevant, which need to be explored in future. However, the key regions have remained conserved over time.
https://www.academia.edu/journals/academia-molecular-biology-and-genomics/articles?source=journal-top-nav
Leadership skills training needs of early career doctors: a European survey Mário J. Santos, Ana Samouco, Zetti Azvee, Deepa Bagepalli Krishnan, Nikola Žaja, João Costa Pedro, Raka Maitra, Alma László, Beatriz Jorge, Matthäus Fellinger, Filipe Grilo, Mariana Pinto da Costa, Uriel Halbreich Volume 3, Issue 1
https://www.academia.edu/2997-9196/3/1/10.20935/MHealthWellB8187
Abstract
Introduction: This study aims to investigate the access to leadership development opportunities among European psychiatric trainees and early career psychiatrists (ECPs) and their perceptions and needs related to leadership skills training.
Materials and methods: This is a cross-sectional study using an online survey. The collected data was statistically analyzed using Stata 13, including an ordered probit regression to study the impact of five demographic characteristics of participants on the prioritization of 18 variables of leadership skills and 12 variables of management skills.
Results: A total of 119 psychiatry trainees from 31 European countries responded to the study, of which 80 (67.2%) were female. Additionally, 48.7% of participants (n = 58) were general adult psychiatric trainees, and 29.4% (n = 35) were ECPs. Our results show that 63.0% (n = 75) had no access to leadership skills training within their training program. Also, respondents tended to be unsatisfied with the training received. More than half (n = 62, 52.1%) of trainees sought additional leadership and management training outside their program. All the participants recommended that training in leadership skills should be included in a psychiatric training program. The top three most important skills to trainees were “communication”, “teamwork”, and “empathy and cultural sensitivity” regarding leadership skills; and “stress management”, “time management”, and “crisis management” concerning management skills.
Conclusions: Our study provides an overview of important gaps in the need, availability, and access to leadership skills training amongst psychiatric trainees and ECPs across Europe. We hope this study will help inform future developments and improvements in leadership skills training for trainees and ECPs across Europe.
https://www.academia.edu/journals/academia-mental-health-and-well-being/articles?source=journal-top-nav
domingo, 15 de marzo de 2026
Gut microbes help turn white fat into calorie-burning beige fat A new study shows how specific gut bacteria work with diet to trigger fat browning in mice, revealing potential pathways for future metabolic therapies.
https://www.drugdiscoverynews.com/gut-microbes-help-turn-white-fat-into-calorie-burning-beige-fat-17065
When we think about fat, we most often imagine white fat cells, which store excess calories like tiny batteries, providing insulation and cushioning for muscles, bones, and organs. But not all fat is built to store energy. Brown fat does the opposite, burning calories to generate heat and keep the body warm. And then there is beige fat. First identified in 2008, beige fat resides within white fat tissue but functions like brown fat, efficiently burning energy when the body is exposed to cold.
Weekly Rundown: FDA approves first treatment for rare cerebral folate deficiency Unexpected breakthroughs in drug manufacturing, lawsuits, regulatory updates, and more led the news this week.
https://www.drugdiscoverynews.com/weekly-rundown-fda-approves-first-treatment-for-rare-cerebral-folate-deficiency-17069
The FDA has approved the first treatment for cerebral folate transport deficiency, a rare genetic disorder that impairs folate transport into the brain. Wellcovorin (leucovorin calcium) tablets have traditionally been used to reduce symptoms from high-dose chemotherapy but are now approved for adult and pediatric patients with a confirmed FOLR1 (folate receptor alpha 1) gene variant. This provides the first FDA-sanctioned option for a condition that can cause severe developmental delays, seizures, movement disorders, and other neurological complications. The approval was supported by a systematic review of 26 published case reports and case reviews from 2009 to 2024, covering 46 patients treated through various administration routes. Among 27 patients receiving oral leucovorin, 24 showed clinical improvements, including reduced seizure severity, better motor function, and enhanced communication or behavior. FDA Commissioner Marty Makary called the decision a “significant milestone” for patients who previously had no approved therapies, while officials noted that observational and real-world evidence played a key role in demonstrating clinical benefit. – Bree Foster
Microbes make, stabilize, and test drugs all inside a cell A new bacterial platform can produce millions of stabilized peptides in a single experiment, accelerating the search for therapies against hard-to-drug targets.
https://www.drugdiscoverynews.com/microbes-make-stabilize-and-test-drugs-all-inside-a-cell-17060?utm_campaign=DDN_Newsletter_Science%20Spotlight&utm_medium=email&_hsenc=p2ANqtz--HnIU43LWTvQmvUrjnwI-Jts60wFM0-Rhu70sSeiTydtR19hwi6EFPj5tR6iVGwP74EYmeJw-WZ20Flp2qw2nWY8yNSQ&_hsmi=408663516&utm_content=408663516&utm_source=hs_email
Peptide therapeutics are experiencing a surge of interest, driven by significant advances, including the blockbuster success of weight loss drugs like semaglutide and tirzepatide. With more than 80 peptide drugs already on the market and hundreds more in clinical and preclinical development, the global market for peptide-based therapeutics is expected to grow to $68.83 billion by 2028.
MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study
Articles
MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study +...
Fleur M LouisAnna van der VoortMette S van RamshorstAntonios DaletzakisIngrid A MandjesInge Kemperand others
The Lancet OncologyVol. 27No. 3p349–360
https://www.thelancet.com/collections/tumour-imaging?dgcid=hubspot_email_infocusalerts-oncology_feature&parent=001611&startPage=&utm_campaign=infocusalerts-oncology&utm_medium=email&_hsenc=p2ANqtz-8zORBPB5oOMjMGjJRFxmbfxCo4WHwqNEwUXxyQ-eYVpxP02ggQAvFUEw3VnO-p4q2Pdadgfwsl8UVZYhcs9ozBF5z-1w&_hsmi=408798171&utm_content=408446946&utm_source=hs_email
Published: February 16, 2026
CURE ID App Lets Clinicians Report Novel Uses of Existing Drugs
https://www.fda.gov/drugs/science-and-research-drugs/cure-id-app-lets-clinicians-report-novel-uses-existing-drugs?utm_medium=email&utm_source=govdelivery
On March 15th, International Long COVID Awareness Day, use your experience to guide clinical trials and help countless others suffering with Long COVID.
CURE ID is a treatment registry where patients, care partners, and clinicians unite to share what works, as well as what doesn’t. By using CURE ID, you can
https://cure.ncats.io/pilot-overview/long-covid?utm_medium=email&utm_source=govdelivery
Share unique Long COVID symptoms and/or experiences with treatments and medications
Explore the treatment experiences that have been shared by others
CURE ID, A Tool for Clinicians to Report New Uses of Existing Drugs with Heather Stone and Dr. Marco Schito
Q&A with FDA Podcast | Transcript
https://www.fda.gov/drugs/news-events-human-drugs/cure-id-tool-clinicians-report-new-uses-existing-drugs-heather-stone-and-dr-marco-schito?utm_medium=email&utm_source=govdelivery
Updated EULAR recommendations guide treatment decisions for rheumatoid arthritis
https://www.news-medical.net/news/20260313/Updated-EULAR-recommendations-guide-treatment-decisions-for-rheumatoid-arthritis.aspx
First published in 2010, the EULAR recommendations for the management of RA, the most frequent inflammatory rheumatic disease, have been relied upon by healthcare professionals and organizations worldwide to offer an up-to-date and robust analysis of the effectiveness and practical use of available DMARDs – from conventional agents such as methotrexate to biologics and Janus kinase (JAK) inhibitors. The recommendations were last reviewed in 2022 to include key safety factors. The current fifth update was again based on reviews of the most recent evidence regarding these therapies and provides the most up-to-date guidance. Although there have been no new drugs approved since the last version, deepened insights as well as important strategic developments have accumulated.
Study highlights benefits of specialist resource centers for autistic pupils
https://www.news-medical.net/news/20260313/Study-highlights-benefits-of-specialist-resource-centers-for-autistic-pupils.aspx
Specialist resource centers (a form of 'Inclusion Base') within mainstream secondary schools may be linked to stronger academic progress, improved attendance, and a greater sense of belonging for autistic pupils, according to a new three-year study from the University of Surrey.
How N-Acylethanolamines Control Appetite, Energy Balance, and Metabolic Health
https://www.news-medical.net/health/How-N-Acylethanolamines-Control-Appetite-Energy-Balance-and-Metabolic-Health.aspx
From appetite control to neuroprotection, N-acylethanolamines are emerging as powerful lipid messengers that connect metabolism, inflammation, and brain health through intricate biochemical signaling pathways.
Google’s AI medical assistant shows doctor-level diagnostic reasoning in real clinic study
https://www.news-medical.net/news/20260312/Googlee28099s-AI-medical-assistant-shows-doctor-level-diagnostic-reasoning-in-real-clinic-study.aspx
In a real-world urgent care trial with 100 patients, Google’s conversational AI system, AMIE, safely conducted pre-visit medical interviews and generated diagnostic insights comparable to those of physicians, offering an early glimpse of how AI assistants could transform everyday clinical workflows.
CLINICAL PERSPECTIVES: +++
CLINICAL PERSPECTIVES
Age-Stratified Clinical Burden of Post-Allogeneic HSCT Complications in Hurler Syndrome (MPS IH)
https://checkrare.com/age-stratified-clinical-burden-of-post-allogeneic-hsct-complications-in-hurler-syndrome-mps-ih/
Ali Mohajer, PhD, Qral Group, discusses the age-stratified burden of post-allogeneic hematopoietic stem cell transplantation (post-allo-HSCT) complications in Hurler syndrome (MPS IH).
Committee for Medicinal Products for Human Use Recommendation for Sotatercept for the Treatment of Pulmonary Arterial Hypertension
https://checkrare.com/committee-for-medicinal-products-for-human-use-recommendation-for-sotatercept-for-the-treatment-of-pulmonary-arterial-hypertension/
Marius Hoeper, MD, Respiratory Physician at Hannover Medical School, Germany, discusses a recent regulatory update by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in the treatment of pulmonary arterial hypertension (PAH).
Post Hoc Analysis of Long-Term Efficacy of Migalastat in Females With Fabry Disease
https://checkrare.com/post-hoc-analysis-of-long-term-efficacy-of-migalastat-in-females-with-fabry-disease/
A recent post hoc analysis of long-term efficacy of migalastat in females with Fabry disease was published in the Journal of Medical Genetics.
Feb 27, 2026 This Week in Cardiology Podcast John M. Mandrola, MD February 27, 2026
https://www.medscape.com/viewarticle/1003263#vp_2?ecd=mkm_mscpapp_260314_mscpmrk_podcasts_etid8185165&uac=148436CN&impID=8185165
New Zealand cardiologist and advanced care planning advocate Dr Tammy Pegg wrote to me to say she agreed with my assertion that CPR should be viewed as another medical intervention and therefore its benefit/risk calculus lies with the clinical team, not the patient and family. She wrote: “You can no more demand CPR than you can a laparoscopic cholecystectomy.”
Secondary Hypertension Podcast
https://www.medscape.com/viewarticle/1003186?ecd=mkm_mscpapp_260314_mscpmrk_podcasts_etid8185165&uac=148436CN&impID=8185165
Screening and Management of Primary Aldosteronism: Closing the Gap in Hypertension Care
Marwah Abdalla, MD, MPH; Vivek Bhalla, MD
February 26, 2026
Adding to the Toolbox: Thyroid Artery Embolization Kaniksha Desai, MD; Juan C. Camacho, MD February 24, 2026
Adding to the Toolbox: Thyroid Artery Embolization
Kaniksha Desai, MD; Juan C. Camacho, MD
https://www.medscape.com/viewarticle/1003208?ecd=mkm_mscpapp_260314_mscpmrk_podcasts_etid8185165&uac=148436CN&impID=8185165
February 24, 2026
Breast Cancer and HER2 Podcast
https://www.medscape.com/viewarticle/1002986?ecd=mkm_mscpapp_260314_mscpmrk_podcasts_etid8185165&uac=148436CN&impID=8185165
HER2 Positive, Low, Ultralow: What Testing Means in the ADC Era
Kathy D. Miller, MD; Sunil S. Badve, MD
February 24, 2026
sábado, 14 de marzo de 2026
Highly contagious virus with no treatment spreading rapidly through western state By Melissa Rudy Fox News Published March 6, 2026 3:45pm EST | Updated March 6, 2026 3:30pm EST +++++ +...
Highly contagious virus with no treatment spreading rapidly through western state
Human metapneumovirus, or HMPV, is rampant in Northern California, wastewater data show
Melissa Rudy By Melissa Rudy Fox News
Published March 6, 2026 3:45pm EST | Updated March 6, 2026 3:30pm EST
https://www.foxnews.com/health/highly-contagious-virus-no-treatment-spreading-rapidly-through-western-state?lid=6xqmiu0fslcm
GLP-1 drugs linked to higher fracture risk, osteoporosis and gout, new studies suggest
Researchers say bone health should be assessed before starting medications like Ozempic in adults over 65
By Deirdre Bardolf Fox News
Published March 7, 2026 5:51pm EST
https://www.foxnews.com/health/glp-1-drugs-tied-fracture-risk-older-adults-new-studies-suggest?lid=t12bm45x1c20
Alarming report reveals what’s driving deadly cancer surge in young adults
And more of this week's top health stories, right to your inbox
By Fox News Staff Fox News
Published March 6, 2026 5:01pm EST
https://www.foxnews.com/health/alarming-report-reveals-whats-driving-deadly-cancer-surge-young-adults?lid=427kgm30gkba
‘Fire-breathing’ trend linked to severe burns in teens, officials warn
Pennsylvania teen was reportedly intubated after suffering burns to the face and chest from isopropyl alcohol stunt
Angelica Stabile By Angelica Stabile Fox News
Published March 7, 2026 4:14pm EST
https://www.foxnews.com/health/fire-breathing-trend-linked-severe-burns-teens-officials-warn?lid=zwwgqo93rm5c
Toxic people in your life may have a hidden health impact, study suggests
Difficult family members and friends accelerate biological aging, research reveals
Angelica Stabile By Angelica Stabile Fox News
Published March 13, 2026 6:00am EDT
https://www.foxnews.com/health/toxic-people-your-life-may-have-hidden-health-impact-study-suggests?lid=fzafn6zv9t0t
Nearly half of seniors improve with age — and researchers think they know why
Nearly half of adults 65 and older showed improvements in cognitive and/or physical function
By Khloe Quill Fox News
Published March 11, 2026 3:05pm EDT
https://www.foxnews.com/health/nearly-half-seniors-improve-age-researchers-think-know-why?lid=gfkflhycmesk
Sugary drinks linked to higher anxiety risk in certain age group, study finds (+...)
https://www.foxnews.com/health?lid=b5i3ecdt3inp
Cannabis compounds could reverse disease affecting one-third of adults By Khloe Quill Fox News Published March 9, 2026 5:17pm EDT
Cannabis compounds could reverse disease affecting one-third of adults
Two compounds significantly improved metabolic health and liver function in those with common disease
By Khloe Quill Fox News
Published March 9, 2026 5:17pm EDT
https://www.foxnews.com/health/cannabis-compounds-could-reverse-disease-affecting-one-third-adults?lid=owlycupnc5la
Ancient herb known as ‘nature’s Valium’ touted for improving sleep and anxiety By Angelica Stabile Fox News Published March 8, 2026 9:00am EDT
Ancient herb known as ‘nature’s Valium’ touted for improving sleep and anxiety
Valerian shows some benefits in trials, but doctors disagree on comparisons to prescription drug
Angelica Stabile By Angelica Stabile Fox News
Published March 8, 2026 9:00am EDT
https://www.foxnews.com/health/ancient-herb-known-natures-valium-touted-improving-sleep-anxiety?lid=yzh29qv7w4dq
Can Deep Brain Stimulation Solve the Mystery of Pain? By Ivanhoe Broadcast News on March 9, 2026
ORLANDO, Fla. (Ivanhoe Newswire) — Chronic pain is any pain that lasts longer than three months. It can also be inconsistent, a constant ache or sudden flares. The main problem in solving it is that there are many different causes including arthritis, back pain, cancer, fibromyalgia, headaches, neck, and nerve pain. Deep Brain Stimulation
https://www.ivanhoe.com/family-health/can-deep-brain-stimulation-solve-the-mystery-of-pain/
Driven By Her Own Pain: First At-Home Test for Endometriosis By Ivanhoe Broadcast News on March 11, 2026
CINCINNATI, Ohio. (Ivanhoe Newswire) — Endometriosis is a painful and often debilitating disease that affects an estimated 6.5 million women in the U.S. It occurs when tissue similar to the lining of the uterus grows outside of it, causing pain, inflammation, and sometimes infertility. Despite the staggering numbers, doctors and patients say research has been chronically underfunded. NIH has spent less than one-tenth of 1% of its budget over the past decade to study the disease. Now, one researcher is using her own struggle to bring hope to millions.
https://www.ivanhoe.com/family-health/driven-by-her-own-pain-first-at-home-test-for-endometriosis/
Women In 2026: Progress, Power & Pushback By Ivanhoe Broadcast News on March 12, 2026
Orlando, Fla. (Ivanhoe Newswire) — Women’s History Month is often about how far women have come but new data shows the story is more complicated. From winning the right to vote to breaking barriers in politics, science, sports, and business, women have made historic gains over the last century. Today women are more educated, more represented, and more visible than ever before, but in some key areas progress has stalled and in others, it’s actually moving backward.
https://www.ivanhoe.com/family-health/women/women-in-2026-progress-power-pushback/
Breathing Pain Free After Heart Surgery! By Ivanhoe Broadcast News on March 5, 2026
CLEVELAND, Ohio. (Ivanhoe Newswire) — Imagine your heart not functioning properly and you not knowing for years! That’s the reality of people with aortic valve disease. Symptoms include chest pain, dizziness, fatigue, and irregular heartbeat. If the disease is above a mild or moderate state, the only option has been surgery. But now there’s a new option.
https://www.ivanhoe.com/family-health/breathing-pain-free-after-heart-surgery/
Breakthroughs For Dry Macular Degeneration Are on the Way By Ivanhoe Broadcast News on March 10, 2026
ORLANDO, Fla. (Ivanhoe Newswire) — There are two types of macular degeneration: dry and wet. Dry age-related macular degeneration is the most common type — it happens when small deposits form under the retina, causing cells in the eye’s macula to die off. There’s currently no cure, but breakthroughs are on the horizon.
https://www.ivanhoe.com/family-health/breakthroughs-for-dry-macular-degeneration-are-on-the-way/
March Madness: Why We Root For The Underdogs By Ivanhoe Broadcast News on March 16, 2026
Orlando, Fla. (Ivanhoe Newswire) — It’s that time of year, March Madness! Where our favorite college teams vie for the title. Every tournament has its favorites and then it seems every year there’s the team everyone can’t stop rooting for, the underdog. Studies show 88 percent of people root for the underdog, even when the stats and the experts say they don’t stand a chance. So why do we cheer for the long shot?
https://www.ivanhoe.com/?p=36810&preview=1&_ppp=0ee40fdf89
Hidden Sugar-Hidden Heart Risk By Ivanhoe Broadcast News on March 17, 2026
Orlando, Fla. (Ivanhoe Newswire) — Experts say one heart risk factor often flies under the radar: blood sugar swings. Nearly 98 million American adults have prediabetes, and more than 80 percent don’t know it. Many people associate blood sugar with diabetes, but doctors say repeated spikes and crashes can affect anyone, increasing inflammation and raising heart disease risk. Experts say millions may be stressing their hearts simply by choosing the wrong “healthy” foods.
https://www.ivanhoe.com/?p=36813&preview=1&_ppp=a4673eca30
Revenge Quitting Vs. Quitting Well: How You Leave Matters! By Ivanhoe Broadcast News on March 18, 2026
Orlando, Fla. (Ivanhoe Newswire) — The job market is in turmoil right now. Business Insider has declared it “the big freeze,” where companies aren’t hiring or firing. As of October, you are more likely to get into Harvard then a new job. But for some people, staying at their current job seems like a worse fate.
https://www.ivanhoe.com/?p=36816&preview=1&_ppp=2bcd67d55f
Tracking Teens: When Safety Becomes Surveillance By Ivanhoe Broadcast News on March 19, 2026
Orlando, Fla. (Ivanhoe Newswire) — Smartphones, GPS apps, and air tags have made it easier than ever for parents to know where their kids are and what they’re doing. In fact, studies show about half of U.S. parents now use location-tracking apps to monitor their teens. Supporters say it’s about safety. Critics warn it can cross the line from protection to surveillance. So, when does tracking help and when can it actually hurt?
https://www.ivanhoe.com/?p=36819&preview=1&_ppp=5bf601f07f
The Shape Of Your Health By Ivanhoe Broadcast News on March 20, 2026
Orlando, Fla. (Ivanhoe Newswire) — Research shows more than a third of young women and a quarter of young men weigh themselves at least once a week. But when it comes to your health, it’s not just about the numbers on the scale. Where you carry weight, not just how much can affect your risk for heart disease, diabetes, even cancer.
https://www.ivanhoe.com/?p=36822&preview=1&_ppp=de1c01fc59
Designing evidence-based digital mental health check-ins in higher education Madison Westley [1] , Jennifer Laffier* [1] , Aalyia Rehman [1] , Gorm Eriksen [2] , Rune Sønderby [2] , Morten Sørdahl [2]
https://www.academia.edu/2997-9196/3/1/10.20935/MHealthWellB8157
Abstract
Introduction: Due to the urgent need for more sustainable support for post-secondary student mental health, many institutions are exploring alternative ideas for intervention, such as the role of technology, including artificial intelligence (AI) and wellness apps. However, if technological programs or devices are used for student mental health, their design and delivery should align with research on student well-being, best practices in psychological interventions, and learning theories.
Materials and methods: This study used a case study approach to examine how cognitive, industrial, and positive psychology principles can inform the design and delivery of mental health apps and programs. An emerging platform from Denmark, StudentPulse, which has students complete mental health check-ins, was examined using a comparison analysis approach between design features and research on post-secondary wellness and learning.
Results: The analysis revealed how the platform’s features are rooted in three areas of psychological wellness: cognitive, positive, and industrial. This included design features such as AI-trained responses for students that provide immediate feedback, choice, reflection, and flourishing questions. The feedback design is based on cognitive principles of retention, attention, and motivation.
Conclusions: As post-secondary institutions continue to adopt technological tools that support student mental health, these tools must be grounded in psychological principles to ensure they minimize harm and promote student wellness. The study recommends that wellness-based technologies incorporate evidence-based research in mental health, learning, and psychology in their design and implementation.
https://www.academia.edu/journals/academia-mental-health-and-well-being/articles?source=journal-top-nav
RARE Disease Day special edition
https://editions.rarerevolutionmagazine.com/html5/reader/production/default.aspx?pubname=&edid=b226070d-f1dd-4177-bfbc-65a7f9ba2588&pnum=29
Rett syndrome is often framed as a staged, progressive disorder, yet paediatric neurologist Dr Elena González-Alguacil sees something more complex: a non-degenerative but constantly evolving neurodevelopmental “puzzle”, where new symptom clusters emerge and interact across the lifespan. From coordinating a multidisciplinary clinic in Madrid to refining Rett-specific outcome measures and leading research on epilepsy, sleep and comorbidities, she is helping clinicians and families navigate prognosis, measurement and meaningful change in an era of growing possibility. Read
Back to basics in sickle cell disease The Lancet ++... +... +
Back to basics in sickle cell disease
The Lancet
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00506-4/fulltext?dgcid=raven_jbs_etoc_email
Mar 14, 2026
Volume 407Number 10533p1029-1118, e6
https://www.thelancet.com/journals/lancet/issue/vol407no10533/PIIS0140-6736(26)X2008-6
Editorial
Amplifying African voices to lead science for better health
The Lancet Regional Health – Africa
https://www.thelancet.com/issue/S3050-5011(26)X2001-6
Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis
Prof Amar U Kishan, MDa,† aukishan@mednet.ucla.edu ∙ Yilun Sun, PhDf,† ∙ Prof Christopher C Parker, MDi,j ∙ Prof Paul Sargos, MDl ∙ Prof Matthew R Sydes, MSck ∙ Sylvie Chabaud, MScm ∙ et al.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00137-6/fulltext?dgcid=raven_jbs_etoc_feature_lancet
viernes, 13 de marzo de 2026
Deep remission in early relapse 2L DLBCL with COLUMVI + GemOx 56~ durable CR in early relapse 2L DLBCL at 3 years
https://mcj20l77mmv6zbm64ff24smgz911.pub.sfmc-content.com/m2x3t01tdmu?cid=na5589337334&utm_source=medscape&utm_medium=na&utm_campaign=columvi_branded_phase2&utm_content=tx%3Anc3yosdata%3A2512%3Axx&dclid=CjkKEQjw687NBhCM3eyk7NqR_qgBEiQAhPZfllSj2GnUd4bzsCi887ju7qZJJSl31TosJ7ejhjMojAvw_wcB&gad_source=7&gad_campaignid=23190769370
At 3 years, COLUMVI + GemOx continues to deliver a sustained overall survival benefit with a manageable safety profile. As the first and only off‑the‑shelf therapy with curative potential in 2L DLBCL, COLUMVI + GemOx is now recommended by EHA and ESMO Guidelines with the highest category of evidence (I,A).1-6
COLUMVI in combination with gemcitabine and oxaliplatin is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are ineligible for autologous stem cell transplant (ASCT).1
COLUMVI as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.1
Dysuria: When It Hurts to Go With the Flow Josh Palka, DO; Christopher Atalla, DO March 05, 2026 ++++
https://reference.medscape.com/p11/dysuria-when-it-hurts-go-flow-2026a100064x?ecd=wnl_critimg_260313_mscpref_etid8180276&uac=148436CN&impID=8180276
Why Genitourinary Syndrome of Menopause Is Often Missed
Zoé Trinh
https://www.medscape.com/viewarticle/why-genitourinary-syndrome-menopause-often-missed-2025a1000ojg?ecd=wnl_critimg_260313_mscpref_etid8180276&uac=148436CN&impID=8180276
September 17, 2025
Should You Trust the Symptoms? Clinical Judgment in After-Hours Primary Care
Charles P. Vega, MD, FAAFP
https://www.medscape.com/viewarticle/should-you-trust-symptoms-clinical-judgment-after-hours-2025a1000hbf?ecd=wnl_critimg_260313_mscpref_etid8180276&uac=148436CN&impID=8180276
July 01, 2025
Myth of the Month: Altered Urine Is Not Altered Mentation
John E. Kearney, MS; Douglas S. Paauw, MD
https://www.medscape.com/viewarticle/myth-month-altered-urine-not-altered-mentation-2025a1000xqn?ecd=wnl_critimg_260313_mscpref_etid8180276&uac=148436CN&impID=8180276
December 17, 2025
A Decade of Innovation in Breast Cancer (2015-2025): A Comprehensive Review of Clinical Trials, Targeted Therapies and Molecular Perspectives.
https://read.qxmd.com/collection/1133?ecd=wnl_readmost_260313
A Decade of Innovation in Breast Cancer (2015-2025): A Comprehensive Review of Clinical Trials, Targeted Therapies and Molecular Perspectives.
Klaudia Dynarowicz, Dorota Bartusik-Aebisher, Sara Czech, Aleksandra Kawczyk-Krupka, David Aebisher
The past decade has witnessed an unprecedented transformation in breast cancer management, driven by parallel advances in targeted therapies, immunomodulation, drug-delivery technologies, and molecular diagnostic tools. This review summarizes the key achievements of 2015-2025, encompassing all major biological subtypes of breast cancer as well as technological innovations with substantial clinical relevance. In hormone receptor-positive (HR+)/HER2- disease, the integration of CDK4/6 inhibitors, modulators of the PI3K/AKT/mTOR pathway, oral Selective Estrogen Receptor Degraders (SERDs), and real-time monitoring of Estrogen Receptor 1 (ESR1) mutations has enabled clinicians to overcome endocrine resistance and dynamically tailor treatment based on evolving molecular alterations detected in circulating biomarkers...
Energy’s long game: thermogenic adipocytes and the metabolic diseases of modern life Silvia Corvera, Michael P. Czech Volume 4, Issue 1
https://www.academia.edu/journals/academia-biology/articles?source=journal-top-nav
Abstract
The ability to generate, store, and mobilize energy is fundamental to life, and disruptions in these processes underlie metabolic disease. This review examines how these mechanisms evolved to rely profoundly on lipids, a large family of molecules that serve an unusually wide range of biological functions. From early evolutionary times, lipids have enabled chemiosmotic energy transduction, organized the endomembrane systems that synthesize and package neutral lipids, served as concentrated reservoirs of metabolic energy, and functioned as signaling molecules that coordinate cellular and systemic physiology. Adipocytes are specialized cells that can accumulate large amounts of lipid within specialized lipid droplet organelles. Over evolutionary time, mammals developed distinct adipocyte subtypes with tailored physiological roles. White adipocytes, characterized by a single large unilocular lipid droplet, coordinate energy storage and release in response to systemic cues. In contrast, the role of brown and beige adipocytes is to protect the organism from cold exposure by generating heat as a primary output of UCP1-mediated mitochondrial uncoupling. Crucially, this thermogenic process requires extensive systemic coordination: sympathetic neural input triggers lipolysis, vascular networks deliver fuel from multiple adipose depots, and hormonal signals integrate metabolic demand across organs. These requirements position thermogenic adipocytes as metabolic integration “nodes” that orchestrate whole-body fuel allocation and energy homeostasis. The presence of functional thermogenic adipocytes is strongly associated with improved cardiometabolic health, protecting against obesity, type 2 diabetes, and cardiovascular disease. Understanding how these specialized cells sense and respond to systemic signals offers a powerful entry point for developing strategies to counteract metabolic disease.
https://www.academia.edu/2837-4010/4/1/10.20935/AcadBiol8131
Designing evidence-based digital mental health check-ins in higher education Madison Westley, Jennifer Laffier, Aalyia Rehman, Gorm Eriksen, Rune Sønderby, Morten Sørdahl Volume 3, Issue 1
https://www.academia.edu/journals/academia-mental-health-and-well-being/articles?source=journal-top-nav
Abstract
Introduction: Due to the urgent need for more sustainable support for post-secondary student mental health, many institutions are exploring alternative ideas for intervention, such as the role of technology, including artificial intelligence (AI) and wellness apps. However, if technological programs or devices are used for student mental health, their design and delivery should align with research on student well-being, best practices in psychological interventions, and learning theories.
Materials and methods: This study used a case study approach to examine how cognitive, industrial, and positive psychology principles can inform the design and delivery of mental health apps and programs. An emerging platform from Denmark, StudentPulse, which has students complete mental health check-ins, was examined using a comparison analysis approach between design features and research on post-secondary wellness and learning.
Results: The analysis revealed how the platform’s features are rooted in three areas of psychological wellness: cognitive, positive, and industrial. This included design features such as AI-trained responses for students that provide immediate feedback, choice, reflection, and flourishing questions. The feedback design is based on cognitive principles of retention, attention, and motivation.
Conclusions: As post-secondary institutions continue to adopt technological tools that support student mental health, these tools must be grounded in psychological principles to ensure they minimize harm and promote student wellness. The study recommends that wellness-based technologies incorporate evidence-based research in mental health, learning, and psychology in their design and implementation.
https://www.academia.edu/2997-9196/3/1/10.20935/MHealthWellB8157
Researchers develop AI tool to predict patients at risk of intimate partner violence
Researchers develop AI tool to predict patients at risk of intimate partner violence
NIH-funded, automated clinical decision support could facilitate timely interventions for at-risk patients years before they might otherwise seek help.
https://www.nih.gov/news-events/news-releases/researchers-develop-ai-tool-predict-patients-risk-intimate-partner-violence
About Intimate Partner Violence
https://www.cdc.gov/intimate-partner-violence/about/index.html
Automated IPV Risk Support System
An AI-driven system helping healthcare clinicians identify and support patients at risk for Intimate Partner Violence
https://bhartikhurana.bwh.harvard.edu/airs/
Eye on the Future Teen Video Contest
Eye on the Future Teen Video Contest
U.S. high school students, show us your science for a chance to win a cash prize! But hurry—this year’s contest closes on April 19th, 2026 at 11:59 pm Eastern Time or once the first 300 submissions have been received.
https://www.nei.nih.gov/about/education-and-outreach/eye-future-teen-video-contest
Traumatic Brain Injury (TBI)
Traumatic Brain Injury (TBI)
TBI is an injury from some type of trauma, such as a blow, jolt, or penetrating object, that disrupts normal brain functions. Falls, car accidents, impact while playing sports, and objects piercing the skull are common causes of TBI. A TBI can range from mild, sometimes called a concussion, to serious, which can cause long-term problems. NICHD is one of many NIH institutes and other federal agencies working to understand and prevent TBI and to help people recover from TBI and related conditions.
https://www.nichd.nih.gov/health/topics/tbi
NWGHAAD 2026: Reset Your Routine
https://www.hiv.gov/blog/nwghaad-2026-reset-your-routine?utm_source=newsletter&utm_medium=email&utm_campaign=blog&j=2923529&sfmc_sub=6992026&l=6498_HTML&u=72555887&mid=100006181&jb=0
National Women and Girls HIV/AIDS Awareness Day (NWGHAAD), which took place on March 10, is an observance during which we mark the impact of HIV and AIDS on women and girls. For the 2026 awareness day, HIV.gov highlighted the importance of HIV testing, prevention, and care and how these efforts are critical to protecting the health of women.
A Narrative Review of Alcohol Prevention Interventions Among Older Adults Alexis Kuerbis,1 ORCID logo Silke Behrendt,2,3 Alex Elswick,4 Amy F. Kostelic,4 and Simone Schultz5
https://arcr.niaaa.nih.gov/volume/45/1/narrative-review-alcohol-prevention-interventions-among-older-adults?utm_source=arcr-email&utm_medium=email&utm_campaign=kuerbis-2025-11&utm_content=arcr-listserv
A Narrative Review of Alcohol Prevention Interventions Among Older Adults
Alexis Kuerbis, Silke Behrendt, Alex Elswick, Amy F. Kostelic, and Simone Schultz
With the aging of the U.S. population, alcohol misuse among people age 50 and older is an increasing public health challenge. A new Alcohol Research: Current Reviews article summarizes recent research on prevention interventions to address this concern, including older adult-specific interventions. The studies identified both factors that may increase success of prevention interventions in older adults and barriers that can impede intervention success. Offering older adults a variety of intervention modalities, including in-person, mail-based, and digital approaches, may increase access to and engagement with interventions across generations
jueves, 12 de marzo de 2026
Combat Medical raises £2.6 million Series A to advance treatment of BCG unresponsive bladder cancer
https://www.news-medical.net/news/20260312/Combat-Medical-raises-c2a326-million-Series-A-to-advance-treatment-of-BCG-unresponsive-bladder-cancer.aspx
Combat Medical (Combat), a medical device company optimizing the delivery and efficacy of cancer therapeutics, today announced it has raised £2.6 million in the first close of a Series A financing to advance its hyperthermic intravesical chemotherapy treatment, HIVEC® through phase 3 clinical trials and toward FDA registration. The round was led by T&J Meyer Family Foundation, and included investment from Varia Ventures, NW Angel Fund and non-institutional family offices and individuals.
Amarasate and the Gut “Bitter Brake”: A Natural Mechanism for Appetite Regulation
https://www.news-medical.net/health/Amarasate-and-the-Gut-e2809cBitter-Brakee2809d-A-Natural-Mechanism-for-Appetite-Regulation.aspx
Amarasate, a bitter hop extract from Humulus lupulus, has been investigated for its ability to activate gastrointestinal bitter taste receptors and influence appetite-related hormone signaling. Short-term clinical trials suggest the extract can reduce subjective hunger and energy intake in healthy adults, although long-term weight-loss outcomes remain unproven.
AI in Food: How Artificial Intelligence is Designing Healthier and More Sustainable Foods
https://www.news-medical.net/health/AI-in-Food-How-Artificial-Intelligence-is-Designing-Healthier-and-More-Sustainable-Foods.aspx
Artificial intelligence is reshaping the journey from ingredient discovery to personalized nutrition, revealing how data-driven food design could transform human health, sustainability, and the future of what we eat.
Cell-Cultured Fat and Its Role in Improving Flavor and Texture of Alternative Meat Products
https://www.news-medical.net/health/Cell-Cultured-Fat-and-Its-Role-in-Improving-Flavor-and-Texture-of-Alternative-Meat-Products.aspx
Cell-cultured fat is an emerging cellular agriculture technology that produces animal adipose tissue from cultured cells to replicate the flavor, texture, and nutritional properties of conventional meat fats. It offers a promising functional ingredient for improving plant-based and hybrid meat products while potentially reducing environmental impacts and reliance on livestock production.
Filling the treatment gaps in osteoporosis: osteoimmunology as a new frontier eBioMedicine ++ ++...
Progesterone-associated adjustments in brain structure during menstruation and the periovulatory phase—an MRI study
Susanne Nehlsa snehls@ukaachen.de ∙ Elena Lossea ∙ Maya Armina ∙ Ute Habela,c,d ∙ Natalia Chechko
https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(26)00065-4/fulltext?dgcid=raven_jbs_etoc_feature_ebiom
Interstitial cystitis: a phenotype and rare variant exome sequencing study
Joshua E. Motelowa ∙ Ayan Malakarb,d ∙ Sarath Babu Krishna Murthyb,c ∙ Miguel Verbitskyb ∙ Atlas Kahnb ∙ Elicia Estrellae ∙ et al.
https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(26)00031-9/fulltext?dgcid=raven_jbs_etoc_feature_ebiom
Filling the treatment gaps in osteoporosis: osteoimmunology as a new frontier
eBioMedicine
https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(26)00103-9/fulltext?dgcid=raven_jbs_etoc_email
Issue cover
Mar 2026
Volume 125
https://www.thelancet.com/journals/ebiom/issue/vol125nonull/PIIS2352-3964(26)X2001-1
Editorial Legislation on young people's social media use requires evidence-based decisions eClinicalMedicine +++ +...
Aetiology of sepsis in adults living with HIV in East Africa: a secondary analysis of an open-label, multicentre, randomised, controlled phase 3 trial
Eva Otoupalovaa,j eotoupalova@tulane.edu ∙ Lucas Ampaireb,j ∙ Megan Nullc ∙ Buliga Mujagad ∙ Jie Liuc ∙ Bibie Saide ∙ et al.
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00654-6/fulltext?dgcid=hubspot_update_feature_updatealerts_eclinm&utm_campaign=update-eclinm&utm_medium=email&_hsenc=p2ANqtz-9q-2ccweFJ9aVPFJPgkQblN9xN9Z5NQvCbzjCZh6cwMLc6gMbb93zGKjX47K10qJ51OSa-0A6Bht6bpIOEZlPZBxEJ6w&_hsmi=408242639&utm_content=408218086&utm_source=hs_email
Minimally invasive surgical resection reduces one-year mortality, especially in high-risk colon cancer patients: an emulated trial
Daniel O'Learya,d ∙ Camille Maringeb,d camille.maringe@lshtm.ac.uk ∙ Sara Benitez-Majanob ∙ Clemence Leyratc ∙ Bernard Rachetb,e ∙ Manuela Quaresma
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00617-0/fulltext?dgcid=hubspot_update_feature_updatealerts_eclinm&utm_campaign=update-eclinm&utm_medium=email&_hsenc=p2ANqtz-8GC3TZUwISmRHR5XwUnsmXD00gT5-RqafhPrbqHp423BFSPXmMwkdUJiJEcnVKWvkoa8MerKyC42Y5XH_AGW5xx1rf5w&_hsmi=408242639&utm_content=408218086&utm_source=hs_email
Minimum combined sleep, physical activity, and nutrition variations associated with lifeSPAN and healthSPAN improvements: a population cohort study
Nicholas A. Koemela,b,c ∙ Raaj K. Biswasa,b,c ∙ Matthew N. Ahmadia,b,c ∙ Armando Teixeira-Pintod,e ∙ Mark Hamerf,g ∙ Leandro F.M. Rezendeh,i ∙ et al.
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00676-5/fulltext?dgcid=hubspot_update_feature_updatealerts_eclinm&utm_campaign=update-eclinm&utm_medium=email&_hsenc=p2ANqtz-8API2lTQ0hcYSlb5CC21Ej8XAgZlZgc94Ra9h3PYzgAgxiyu6uxrW6KR-nV1Rb5zlEbsxFvgakewNTyELKU8ON2aJqXA&_hsmi=408242639&utm_content=408218086&utm_source=hs_email
Editorial
Legislation on young people's social media use requires evidence-based decisions
eClinicalMedicine
https://www.thelancet.com/journals/eclinm/issue/vol92nonull/PIIS2589-5370(26)X2001-6
Editorial e159 Forging ahead on fibromyalgia The Lancet Rheumatology +++ +...
Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial
Prof Andrew P Cope, MDa andrew.cope@kcl.ac.uk ∙ Marianna Jasenecova, MSca ∙ Joana C Vasconcelos, MScb ∙ Sumera Qureshi, MDa ∙ Dr Karin A van Schie, PhDm ∙ Prof Andrew Filer, MDd ∙ et al. S
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00371-6/fulltext?dgcid=hubspot_update_feature_updatealerts_lanrhe&utm_campaign=update-lanrhe&utm_medium=email&_hsenc=p2ANqtz-9OP--HQzGmo9zM2_U9WtSMAfpL4BLP2TzPHagzXUFnfPbjUALFJ1BpiDRPBeTx4D4VIph6kYTD3VZ-hL8VgfZyrvSN7w&_hsmi=408213663&utm_content=408213663&utm_source=hs_email
Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries
Eleana Bolla, MDa ∙ Anne Grete Semb, MDb ∙ Prof Michelle Petri, MDc ∙ Prof Petros P Sfikakis, MDa ∙ Bahar Artim-Esen, MDd ∙ Gabriela Hernandez-Molina, MDe ∙ et al.
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00257-7/abstract?utm_campaign=update-lanrhe&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanrhe&_hsenc=p2ANqtz-88t3RL3WKMf8shxLPZ6WRT-2-b0G5grIv39-ldLgWiw7Ce4DLrHzffAhjxCusG5GxfXFY5GgRiABDLDEwEcEkjaFPg6w&_hsmi=408213663&utm_content=408213663&utm_source=hs_email
The path to interception in psoriatic disease: from conceptual clarity to clinical translation
Dylan McGagh, BMBCha,b dylan.mcgagh@ndorms.ox.ac.uk ∙ Ashley Elliott, PhDc ∙ Teresa Grohmann, PhDd ∙ Wendy Wagenaar, PhDe,f ∙ Prof Stephen R Pennington, PhDd ∙ Prof Oliver FitzGerald, MDd ∙ et al.
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00348-0/abstract?utm_campaign=update-lanrhe&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanrhe&_hsenc=p2ANqtz-9R9O0_Nk6S1aWrTrKz88nubYA81bj-XOi_82HkYAdZ21EjNKU0pM36Yhnmmt9du1vA1rlFkxKF10JreYvAJqE-5s7r_Q&_hsmi=408213663&utm_content=408213663&utm_source=hs_email
Editorial
e159
Forging ahead on fibromyalgia
The Lancet Rheumatology
https://www.thelancet.com/journals/lanrhe/issue/vol8no3/PIIS2665-9913(26)X2002-1
Preventive cholera vaccination resumes The Lancet Gastroenterology & Hepatology ++... ++
Preventive cholera vaccination resumes
The Lancet Gastroenterology & Hepatology
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(26)00056-7/fulltext?dgcid=raven_jbs_etoc_email
Apr 2026
Volume 11Number 4p267-344, e6
https://www.thelancet.com/journals/langas/issue/vol11no4/PIIS2468-1253(26)X2002-7
Ileocaecal resection versus infliximab for ileal Crohn's disease: retrospective 10-year follow-up of the LIR!C trial
Lotte Oldenburg, MSca,c,† ∙ Anouck E G Haanappel, MScb,† ∙ Mahsoem Ali, MScb ∙ Carolijn Bosman, MSca ∙ Christianne J Buskens, MDb ∙ Prof Cyriel Y Ponsioen, MDa ∙ et al.
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00374-7/abstract?dgcid=raven_jbs_etoc_feature_langas
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial
Millie Long, MDa,* millie_long@med.unc.edu ∙ Jessica R Allegretti, MD MPHb,* ∙ Prof Silvio Danese, MDc ∙ Matthew Germinaro, MDd ∙ Thomas Baker, MDd ∙ Yelina Alvarez, MD PhDd ∙ et al.
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00322-X/abstract?dgcid=raven_jbs_etoc_feature_langas
CONSORT-C: a shared responsibility for truth and quality The Lancet Child & Adolescent Health ++... ++
CONSORT-C: a shared responsibility for truth and quality
The Lancet Child & Adolescent Health
https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(26)00041-6/fulltext?dgcid=raven_jbs_etoc_email
Apr 2026
Volume 10Number 4p233-308, e15
https://www.thelancet.com/journals/lanchi/issue/vol10no4/PIIS2352-4642(26)X2002-8
The association between academic pressure and adolescent depressive symptoms and self-harm: a longitudinal, prospective study in England
Xuchen Guo, MSca,* ∙ Marie A E Mueller, PhDa,* ∙ Jessica M Armitage, PhDb,c ∙ Prof Chris Bonell, PhDd ∙ Prof Tamsin J Ford, MD PhDe ∙ Prof Ann John, MD PhDf ∙ et al.
https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(25)00342-6/fulltext?dgcid=raven_jbs_etoc_feature_lanchi
CONSORT-Children and Adolescents (CONSORT-C) 2026 extension statement: enhancing the reporting and impact of paediatric randomised trials
Ami Baba, MResa ∙ Maureen Smith, MEdb ∙ Prof Beth K Potter, PhDc ∙ Prof An-Wen Chan, MD DPhild ∙ Prof David Moher, PhDc,e ∙ Alene Toulany, MD MSca,f,g,h,i ∙ et al.
https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(26)00004-0/fulltext?dgcid=raven_jbs_etoc_feature_lanchi
Rare Disease Focus: Lung Diseases +++ +++ +
CLINICAL PERSPECTIVES
Committee for Medicinal Products for Human Use Recommendation for Sotatercept for the Treatment of Pulmonary Arterial Hypertension
https://checkrare.com/committee-for-medicinal-products-for-human-use-recommendation-for-sotatercept-for-the-treatment-of-pulmonary-arterial-hypertension/
Marius Hoeper, MD, Respiratory Physician at Hannover Medical School, Germany, discusses a recent regulatory update by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in the treatment of pulmonary arterial hypertension (PAH).
Approval of Nerandomilast Tablets To Treat Patients With Progressive Pulmonary Fibrosis
https://checkrare.com/approval-of-nerandomilast-tablets-to-treat-patients-with-progressive-pulmonary-fibrosis/
Shervin Assassi, MD, Director, Division of Rheumatology at McGovern Medical School, discusses the approval of Jascayd (nerandomilast) tablets for treatment of patients with progressive pulmonary fibrosis (PPF).
New Formulation of Berotralstat for Treatment of Pediatric Patients With Hereditary Angioedema
https://checkrare.com/new-formulation-of-berotralstat-for-treatment-of-pediatric-patients-with-hereditary-angioedema/
Raffi Tachdjian, MD, Associate Clinical Professor of Medicine & Pediatrics, Division of Allergy & Clinical Immunology, University of California Los Angeles, discusses a new formulation of Orladeyo (berotralstat) for the treatment of pediatric patients with hereditary angioedema (HAE).
Rare Diseases in Ireland – New Efforts to Improve Access to Care
https://checkrare.com/rare-diseases-in-ireland-new-efforts-to-improve-access-to-care/
Each country takes a different approach to rare diseases, from the way it defines the term to the health policies it implements to its approach to research.
Data From the CORAL Trial of Nalbuphine ER in Patients With Idiopathic Pulmonary Fibrosis
https://checkrare.com/data-from-the-coral-trial-of-nalbuphine-er-in-patients-with-idiopathic-pulmonary-fibrosis/
Data from the Phase 2b CORAL trial of nalbuphine extended release (ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) was published in the Journal of the American Medical Association (JAMA).
Open-Label Extension Study Testing Arimoclomol in Patients With NPC
https://checkrare.com/open-label-extension-study-testing-arimoclomol-in-patients-with-npc/
A recent paper published in Molecular Genetics and Metabolism presented safety and efficacy outcomes from the 48-month open-label extension of the NPC-002 study of arimoclomol in patients with Niemann Pick type C.
A Family’s Experience With Nasopharyngeal Carcinoma
https://checkrare.com/a-familys-experience-with-nasopharyngeal-carcinoma/
Floyd Stewart, patient with stage 4 nasopharyngeal carcinoma, and Monique Stewart, advocate and Floyd’s wife, discuss their family’s experience with the disease and their advocacy work.
Clinical Advances in Modern Gastrointestinal Cancer Therapies +++
https://www.medscape.org/sites/advances/gi-cancers?src=mkmcmr_driv_32025_mscpedu_416293.23_ace_launch-ret&sso=true&uac=148436CN
Shaping the Future: Expert Insights on Perioperative Immunotherapy for Gastric/GEJ Cancers
Authors:
Elizabeth Smyth, MD; Samuel J. Klempner, MD, FASCO, Eric Van Cutsem, MD, PhD
https://www.medscape.org/viewarticle/1002919?src=mkmcmr_driv_32025_mscpedu_416293.23_ace_launch-ret&sso=true&uac=148436CN
Quickfire Updates on Gastric/GEJ Cancers: Latest Data in Perioperative Immunotherapy
Authors:
Geoffrey Ku, MD; Elizabeth Smyth, MD
https://www.medscape.org/viewarticle/1002710?uac=148436CN&src=mkmcmr_driv_32025_mscpedu_416293.23_ace_launch-ret&sso=true
When should statins be used for primary prevention of cardiovascular disease? (Medscape AI) ++++
https://www.medscape.com/ai-search?query=When%20should%20statins%20be%20used%20for%20primary%20prevention%20of%20cardiovascular%20disease%3F&ecd=wnl_tp10_daily_260308_MSCPEDIT_etid8160845&uac=148436CN&impID=8160845
Does minor papillotomy change rates of chronic pancreatitis, diabetes, or exocrine dysfunction? (Medscape AI)
https://www.medscape.com/ai-search?query=Does%20minor%20papillotomy%20change%20rates%20of%20chronic%20pancreatitis,%20diabetes,%20or%20exocrine%20dysfunction%3f&ecd=wnl_tp10_daily_260303_MSCPEDIT_etid8150037&uac=148436CN&impID=8150037
How is doomscrolling reshaping adolescent attention and autonomy? (Medscape AI)
https://www.medscape.com/ai-search?query=How%20is%20doomscrolling%20reshaping%20adolescent%20attention%20and%20autonomy%3f&ecd=wnl_tp10_daily_260302_MSCPEDIT_etid8148274&uac=148436CN&impID=8148274
When is empiric antibiotic therapy indicated in presumed community acquired pneumonia? (Medscape AI)
https://www.medscape.com/ai-search?query=When%20is%20empiric%20antibiotic%20therapy%20indicated%20in%20presumed%20community%20acquired%20pneumonia%3F&&ecd=mkm_ret_260312_mscpmrk-OUS_DisReferences_etid8171899&uac=148436CN&impID=8171899
Rapid Review Quiz: Crohn’s Disease 2025 Management Guidelines Sarah El-Nakeep, MD February 19, 2026 ++++
https://reference.medscape.com/viewarticle/rapid-review-quiz-crohns-disease-2025-management-guidelines-2026a10004ji?ecd=WNL_rrq_260312_MSCPEDIT_etid8174882&uac=148436CN&impID=8174882
Rapid Review Quiz: American Heart Association's New High Blood Pressure Guidelines
Reviewed by Yasmine S. Ali, MD
https://reference.medscape.com/viewarticle/rapid-review-quiz-american-heart-associations-new-high-blood-2025a1000ret?ecd=WNL_rrq_260312_MSCPEDIT_etid8174882&uac=148436CN&impID=8174882
October 22, 2025
Rapid Review Quiz: Recent Research in Peptic Ulcer Disease
Reviewed by Sarah El-Nakeep, MD
https://reference.medscape.com/viewarticle/rapid-review-quiz-recent-research-peptic-ulcer-disease-2025a1000yel?ecd=WNL_rrq_260312_MSCPEDIT_etid8174882&uac=148436CN&impID=8174882
December 19, 2025
Rapid Review Quiz: Plant-based Diets
Romesh Khardori, MD, PhD
https://reference.medscape.com/viewarticle/rapid-review-quiz-plant-based-diets-2026a100031s?ecd=WNL_rrq_260312_MSCPEDIT_etid8174882&uac=148436CN&impID=8174882
February 12, 2026
miércoles, 11 de marzo de 2026
Two paths, one childhood: raising twins when one has a rare muscular dystrophy 11 March 2026 Written by Ashley Burkman
https://rarerevolutionmagazine.com/two-paths-one-childhood-raising-twins-when-one-has-a-rare-muscular-dystrophy/
When people meet my twin boys, the first thing they notice is how alike they are. They share the same age, the same laugh and the same enthusiasm for life. What becomes clear a little later is that their paths through childhood look different.
One of my sons, Carter, was born with a rare congenital muscular dystrophy. His muscles are weaker and fatigue more easily. He uses a power wheelchair for mobility and receives nutrition through a feeding tube. His twin brother, Calvin, does not have a disability. Together they are growing up side by side, shaping each other’s understanding of movement, strength and belonging in ways I never could have imagined.
Immunotherapy for Lymphoma Source: Society for Immunotherapy of Cancer February 20, 2026
https://reference.medscape.com/cc2/p10/sitc-guideline-immunotherapy-lymphoma-2026a10004e3?ecd=WNL_drugguide_260311_MSCPREF_onc_etid8172632&uac=148436CN&impID=8172632
This Medscape summary highlights February 2025 revisions to the SITC clinical practice guideline for immunotherapy in lymphoma, which was originally established in 2020. The summary provides oncologists and hematologists with streamlined recommendations regarding the optimal scheduling and integration of FDA-approved immunotherapies, as well as the specialized management of irAEs.
The guidance is derived from a combination of published literature and expert clinical experience. It incorporates 2025 updates, including revised FDA black box warnings and corrected clinical data. This summary is intended for quick clinical reference; for deep-dive rationale, background, and full evidence tables, please refer to the complete SITC publication.
Suscribirse a:
Comentarios (Atom)
.png)
